<DOC>
	<DOCNO>NCT02303769</DOCNO>
	<brief_summary>Study investigate efficacy safety GL2702 GLARS-NF1tablet Harnal-D - tablet benign prostatic hyperplasia patient low urinary tract symptomatic</brief_summary>
	<brief_title>Study Investigate Efficacy Safety GL2702 GLARS-NF1tablet Harnal-D - Tablet BPH Patients With LUTS</brief_title>
	<detailed_description>GL2702 GLARS-NF1 tablet control release formation make GL Pharm Tech</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Over 50 year old , BPH diagnosted , Adult Male Subject IPSS ≥ 13 point PSA &lt; 4ng/mL 5ml/sec &lt; Qmax ≤ 15ml/sec Prostatic cancer 250ml &lt; PVR ALT AST &gt; 2 time ( Upper Normal Range ) Total Bilirubin &gt; 1.5 time ( Upper Normal Range ) Treated αadrenalin receptor blocker within 2weeks screen Treated 5AlphaReductase Inhibitor within 6 month screen Treated phytotherapy within 2weeks screen Treated Anabolic Steroid within 6 month screen</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Lower Urinary Track Syndrome</keyword>
	<keyword>Harnal</keyword>
	<keyword>Tamsulosin HCL 0.4mg</keyword>
</DOC>